Generative artificial intelligence promises to revolutionize healthcare, influencing areas like drug development and expediting diagnoses. However, the World Health Organization (WHO) issued a cautionary note on Thursday, emphasizing the need for heightened attention to associated risks.
Exploring AI Large Multi-Modal Models (LMMs) in Healthcare
The WHO has been actively evaluating the potential benefits and risks posed by AI Large Multi-Modal Models (LMMs), a relatively recent development rapidly gaining prominence in the healthcare sector. LMMs represent a form of generative AI capable of utilizing diverse data inputs, including text, images, and video, to generate outputs not restricted to the type of data fed into the algorithm.
According to the Manila Bulletin, LMMs are anticipated to find extensive applications in healthcare, scientific research, public health, and drug development. The organization outlined five key areas where this technology could be deployed: diagnosis, scientific research and drug development, medical and nursing education, clerical tasks, and patient-guided use for investigating symptoms.
Balancing Potential With Recognized Risks
While acknowledging the potential benefits, the WHO cautioned against documented risks associated with LMMs. These risks include the potential for generating false, inaccurate, biased, or incomplete outcomes.
The WHO highlighted the inevitability of errors, misuse, and potential harm to individuals as LMMs gain broader usage in healthcare. To address these concerns, the organization issued recommendations on the ethics and governance of LMMs to guide governments, tech firms, and healthcare providers in safely leveraging this technology.
According to WHO, Chief Scientist Jeremy Farrar emphasized the potential of generative AI technologies to improve healthcare but stressed the crucial need for identifying and fully addressing associated risks. The guidance called for collaborative development involving scientists, engineers, medical professionals, and patients.
Additionally, the WHO underscored the vulnerability of LMMs to cybersecurity risks, emphasizing the necessity for regulatory approval, auditing, and impact assessments in healthcare settings. As generative AI continues to evolve, vigilance and ethical considerations remain paramount for its responsible integration into healthcare practices.
Photo: Scott Graham/Unsplash


AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 



